Trials / Available
AvailableNCT06743100
18F-Floretyrosine Expanded Access Program
An Expanded Access Program for the Non-invasive Characterization of Glioma or Treatment Related Change Utilizing Fluorine (F-18) Floretyrosine (18F-FET, TLX101-CDx)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- —
Summary
The aim of this Expanded Access Program (EAP) is to enable the use of 18F-Floretyrosine with positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance (PET/MR) imaging to noninvasively detect tumor burden or treatment related change to assist in optimal management of patients with glioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 18F-Floretyrosine | Single IV administration on Day 0, followed by a PET/CT or PET/MR diagnostic scan 20-40 minutes after the IV administration of 18F-Floretyrosine. |
Timeline
- First posted
- 2024-12-19
- Last updated
- 2025-04-02
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06743100. Inclusion in this directory is not an endorsement.